We are live on
!
Find out more
KCM
Kynam Capital Management Portfolio holdings
AUM
$1.62B
1-Year Est. Return
138.67%
This Fund
S&P 500
This Quarter
Est. Return
-11.08%
1 Year Est. Return
+138.67%
3 Year Est. Return
+268.43%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$392M
AUM Growth
+$83.3M
(+27%)
Cap. Flow
+$144M
Cap. Flow
% of AUM
36.67%
Top 10 Holdings %
Top 10 Hldgs %
78.59%
Holding
39
New
6
Increased
17
Reduced
11
Closed
5
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
GBT
Global Blood Therapeutics, Inc.
GBT
|
+$25.2M |
| 2 |
Vera Therapeutics
VERA
|
+$17.8M |
| 3 |
BNR
Burning Rock Biotech
BNR
|
+$15.7M |
| 4 |
Celldex Therapeutics
CLDX
|
+$11M |
| 5 |
Natera
NTRA
|
+$10.1M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Xenon Pharmaceuticals
XENE
|
+$9.32M |
| 2 |
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
|
+$6.2M |
| 3 |
RDUS
Radius Health, Inc.
RDUS
|
+$1.64M |
| 4 |
Krystal Biotech
KRYS
|
+$1.22M |
| 5 |
Wave Life Sciences
WVE
|
+$414K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 97.91% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Puma Biotechnology
PBYI
$406M
| $1.65M | 0.42% |
579,915
-73,530
| -11% | -$183K |
|
27
Olema Pharmaceuticals
OLMA
$1.02B
| $1.01M | 0.26% |
249,229
-31,598
| -11% | -$100K |
|
28
PUT
Alnylam Pharmaceuticals
ALNY
$36.3B
| $925K | 0.24% |
+50,000
| New | +$7.09M |
|
29
Seres Therapeutics
MCRB
$48M
| $887K | 0.23% |
12,932
-1,640
| -11% | -$141K |
|
|
CNTB
30
Connect Biopharma Holdings
CNTB
$135M
| $643K | 0.16% |
739,649
+511,890
| +225% | +$754K |
|
31
Cabaletta Bio
CABA
$439M
| $580K | 0.15% |
546,800
-69,325
| -11% | -$98K |
|
|
KRTX
32
PUT
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
| $578K | 0.15% |
+38,900
| New | +$4.47M |
|
33
Gyre Therapeutics
GYRE
$662M
| $166K | 0.04% |
12,458
-1,687
| -12% | -$11.2K |
|
34
Neurogene
NGNE
$696M
| $128K | 0.03% |
6,235
-790
| -11% | -$19.3K |
|
|
35
Krystal Biotech
KRYS
$9.88B
| – | – |
-18,393
| Closed | -$1.22M |
|
36
PUT
Nektar Therapeutics
NKTR
$2.39B
| – | – |
-13,333
| Closed | -$260K |
|
37
PUT
TG Therapeutics
TGTX
$8.58B
| – | – |
-258,600
| Closed | -$401K |
|
|
RDUS
38
DELISTED
Radius Health, Inc.
RDUS
| – | – |
-185,514
| Closed | -$1.64M |
|
|
SRRA
39
DELISTED
Sierra Oncology, Inc. Common Stock
SRRA
| – | – |
-193,280
| Closed | -$6.2M |
|
Similar funds
IPW
WIC
HH
TLFA
KCM
PRA
BW
CC
Kynam Capital Management's Q2 2022 Portfolio in Review
As of Q2 2022, Kynam Capital Management held 39 positions worth $392M, up 27% from $308M the previous quarter. Its ten largest holdings account for 79% of the portfolio.
Kynam Capital Management deployed $144M of net new capital in Q2 2022, opening 6 new positions and adding to 17 existing holdings. Its largest new stake was BioCryst Pharmaceuticals: 936,563 shares worth $9.91M.
By sector, the portfolio is most concentrated in Healthcare at 98% of assets, down from 99% a quarter earlier.
On the sell side, the largest reduction was Xenon Pharmaceuticals, an estimated $9.32M trimmed.
- Kynam Capital Management's largest Q2 2022 buy was BioCryst Pharmaceuticals: 936,563 shares worth $9.91M.
- Kynam Capital Management added most to Global Blood Therapeutics, Inc. in Q2 2022, an estimated $25.2M increase.
- Kynam Capital Management's biggest Q2 2022 reduction was Xenon Pharmaceuticals, cutting an estimated $9.32M.
- Kynam Capital Management fully exited Sierra Oncology, Inc. Common Stock in Q2 2022, selling an estimated $6.2M.
- Kynam Capital Management's ten largest holdings make up 79% of its $392M portfolio in Q2 2022.
- Kynam Capital Management opened 6 new positions and closed 5 in Q2 2022.
- Kynam Capital Management's portfolio value rose 27% quarter-over-quarter to $392M.
Based on Kynam Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.